In summary, our study provides data that clearly show that melatonin induces Smad7 expression leading to suppression of TGFβ/Smad-CCL20 activities and EMT in gliomas, indicating that melatonin may be used as a novel therapeutic to treat malignant transformation in gliomas. The gene discussed is TGFB1; the disease is central nervous system cancer.